As previously announced, on April 24, 2023, Spectrum Pharmaceuticals, Inc. (the ?Company?), entered into an Agreement and Plan of Merger (the ?Merger Agreement?) with Assertio Holdings, Inc. (?Assertio?), and Spade Merger Sub 1, Inc. and wholly-owned subsidiary of Assertio (?Merger Sub?). On July 31, 2023 (the ?Closing Date?), pursuant to the terms and conditions set forth in the Merger Agreement, Merger Sub was merged with and into the Company (the ?Merger?) with the Company surviving the Merger as a wholly-owned subsidiary of Assertio (the ?Surviving Corporation?). Pursuant to the Merger Agreement, at the Effective Time, all of the members of the Company?s board of directors (which consisted of William L. Ashton, Brittany K. Bradrick, Seth H.Z. Fischer, Juhyun Lim, Thomas J. Riga and Jeffrey L. Vacirca) ceased to be directors of the Company.